Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. - Wikidata - awgldk - TriplyDB

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

http://www.wikidata.org/entity/Q35547495

about

Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.Inflammatory biomarkers as differential predictors of antidepressant response Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains Experimental medication treatment approaches for depression.New targets for rapid antidepressant action.Clinical applications of hallucinogens: A review.Beyond serotonin: newer antidepressants in the future.GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats.Duality of Antidepressants and Neuroprotectants.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies Current Trends in Identifying Rapidly Acting Treatments for Depression Translational psychiatry--light at the end of the tunnel.New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Ketamine-dependent neuronal activation in healthy volunteers.Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD.Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.Ketamine induced converged synchronous gamma oscillations in the cortico-basal ganglia network of nonhuman primates.Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses.Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model of depression.Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.Comparative Transcriptomic Analysis of the Effects of Antidepressant Drugs in Stress-Susceptible Mice.Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial

P2860

Q27308077-BAB5C764-5C91-4994-A7AA-6C46FF395659 Q28081799-DD62298C-3504-46FF-9859-C2597A5FDF73 Q30830257-2D26040D-A45D-4F9E-9AF7-3D11E0124466 Q33635577-5236C75E-EA76-4159-9F1D-56568228EF9D Q34507177-65487DF3-9F85-4DC0-8DB9-527010CAD348 Q34535259-517587F2-584A-48CE-80EE-5BCF22838603 Q34557706-2A72042F-3147-4F82-B987-63430ED5D16C Q36486035-2DB50FBF-1626-4E1F-BA9C-A085E62435A6 Q36760914-B12D9484-FC00-49D0-BB13-5E3D323AB050 Q36944840-84166233-66E2-4ED9-9D31-7724C53F5E08 Q37114639-044325B6-793B-42AF-8804-B22887EB3A4F Q37210886-0D975335-7486-40CC-9A7F-41B3A57861CA Q38370696-C4C6C54B-4451-46A6-AC1D-76DAD2F8EB9A Q38685420-D6325F51-4A3A-4F4A-9DAC-0434555C3610 Q38787388-636D7FEB-8F9F-4CC2-9F9F-5F29D19C1FB5 Q38793772-574F2C7B-8A65-4109-A991-0D80D29863B3 Q38803371-6FA7E800-6CDC-4DD9-A815-5EC3815149F2 Q38803429-2C2C7FF8-8238-4361-BCF3-C3411E80A359 Q38934855-2C1F43C9-BBCD-49EB-A0F2-C422DB25C4E4 Q39437669-8AFA1C37-218C-471E-88A3-642DDFEF0BAC Q41659149-C4A9F6C2-ED61-4F75-AB1C-95C9838D028F Q41729281-B0F564DF-A7A6-41C7-9D4E-CBE606F99439 Q45326808-DBE0BC6E-6B7F-427C-915B-55ADE5941838 Q47255869-F18462C3-9732-4725-98A0-77B07EF53572 Q47300330-F80D1D8F-AB70-45A5-BC23-FC3A84E13ECC Q47383203-B44096F9-1E45-4558-8269-4BE57202066A Q47616820-635595BF-B5BC-4CD1-A2E2-9676551D071C Q47901145-71B84B9F-F589-449A-A6BC-5DE8C3E7E21B Q48049046-F0926108-7058-4D09-9007-E8354B50F85E Q48067247-31FC148C-9E89-4ADA-A71C-AAA02803F20E Q49712840-8D7F1FA0-0022-470A-9683-809571144D0B Q55078223-C12CB748-37AF-4734-9362-468380707248 Q58213311-1B287112-A3AF-4412-A01B-713EFE1BA2F5 Q58213868-19C2FE35-84DD-4878-B64C-73D509700DA8 Q58213893-49BEE309-5932-4272-A45A-90E641E7E990 Q58696620-CD6C70D0-93DC-44D5-A757-6BAB7936331A

P2860

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

http://www.wikidata.org/entity/Q35547495

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@ast

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@en

type

label

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@ast

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@en

prefLabel

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@ast

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@en

P1433

Q35547495-EF1FBE8F-4A3E-46AD-8AEC-46FF84BCEE39

P1476

Q35547495-3E8A5F30-FF5F-4C08-801B-076F1D7BAC74

P2093

Q35547495-B67DCD4C-523F-428B-9C68-5BE5ACA8C6E8

P2860

Q35547495-031DD83E-5359-432C-A48E-F811BE580498

Q35547495-08D40F6F-006E-46C0-A532-8E8F56F8F72F

Q35547495-0A6F75C7-816F-4886-ABB9-923A58A5B773

Q35547495-0E2D70B5-3B71-43AF-A17F-8D6E84EC343A

Q35547495-0E66E530-0D1A-4F09-88D7-6903A54F7790

Q35547495-11571850-5EE3-4B81-8892-6EF6FCC01A9D

Q35547495-14E4AF30-9D12-4AFC-84C2-CB3961A4087F

Q35547495-183444DA-9403-4C0D-8107-53D3CAFC9519

Q35547495-1E8AF451-A65F-40DF-BEC3-9DFA04E3B83B

Q35547495-2328D666-82C8-4B5A-A6CC-BDFEBB562337

P304

Q35547495-62C701E2-D5E1-4EEE-A3EC-B6B742723968

P31

Q35547495-A7DF8129-956D-47D6-957E-96FF10EE5706

P356

Q35547495-FD3458C2-1F89-403A-96EA-7781FE01E18E

P407

Q35547495-43E0B234-2FCC-4FB4-94A3-EDE482316866

P478

Q35547495-2AAEB2D4-48C2-4D18-B602-48DADFFAB31F

P50

Q35547495-08F68292-2E69-4820-838F-39306F2AE6F6

Q35547495-E469DE6E-869F-4DD7-B65B-358D8FE2D6AD

P577

Q35547495-40896FDA-1860-492A-AADB-9291D9121C0B

P698

Q35547495-8F760CE7-D533-4F48-9F68-9B06CDA5235C

P932

Q35547495-B8B9E36E-865E-431F-9D97-FFE6D1BC75B2

P356

P1433

Annals of the New York Academy of Sciences

P1476

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

@en

P2093

John H Krystal

http://www.w3.org/2001/XMLSchema#string

P2860

Grand challenges in global mental health

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Decreased expression of synapse-related genes and loss of synapses in major depressive disorder

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

A neurotrophic model for stress-related mood disorders

P304

66-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12718

http://www.w3.org/2001/XMLSchema#string

P407

P478

1344

http://www.w3.org/2001/XMLSchema#string

P50

Lynnette A. Averill

P577

2015-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25727103

http://www.w3.org/2001/XMLSchema#string

P932

4412785

http://www.w3.org/2001/XMLSchema#string